Work

858 Long lived vaccine induced T cell clones after individualized messenger RNA neoantigen vaccination in pancreatic cancer

Year: 2026
Type: conference-abstract
Abstract: Background Pancreatic ductal adenocarcinoma (PDAC) is typically immune excluded and poorly responsive to checkpoint inhibition, making it an important test case for whether individualized messenger RNA (mRNA) vaccines can generate clinically meaningful antitumor immunity in low mutation burden tumors. We evaluated whether published prospective evidence supports vaccine induced T cell persistence as a biomarker of delayed recurrence after resection. 1 2Methods A targeted evidence synthesis was performed using PubMed, ClinicalTrials.gov, and published full text reports through June 2026. Eligible studies evaluated individualized mRNA neoantigen vaccination after curative intent resection for PDAC and reported vaccine feasibility, neoantigen specific T cell induction, recurrence free survival (RFS), overall survival (OS), and longitudinal T cell clone tracking. Data were extracted as published aggregate outcomes; no patient level reanalysis was performed.Results The pivotal phase 1 study treated 16 vaccinated patients with sequential atezolizumab, individualized mRNA neoantigen vaccine containing up to 20 neoantigens, and modified FOLFIRINOX. The vaccine was delivered within benchmarked manufacturing timelines and induced de novo high magnitude neoantigen specific T cells in 8 of 16 patients. At 18 months median follow up, responders had median RFS not reached compared with 13.4 months in nonresponders (P = 0.003). 1 Extended follow up confirmed durability. At median follow up of 3.2 years, responders again had median RFS not reached compared with 13.4 months in nonresponders (P = 0.007; hazard ratio 0.14; 95% confidence interval 0.03 to 0.59), while median OS was not reached in either group.2 Longitudinal clone tracking showed that vaccine induced CD8 positive T cell clones had an average estimated lifespan of 7.7 years after boost, with 86% of clones per patient persisting at substantial frequencies approximately 3 years after vaccination. Recurrent tumors in 2 responders showed evidence of fewer vaccine induced T cells and pruning of vaccine targeted cancer clones.2Conclusions In resected PDAC, individualized mRNA neoantigen vaccination can prime durable CD8 positive T cell clones despite low baseline immunogenicity. These data support long lived vaccine induced T cells as a candidate biomarker of delayed recurrence and justify larger studies testing whether personalized neoantigen vaccines can convert immune cold tumors into vaccine responsive disease.References Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 2023;618:144–150.Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature 2025;639:1042–1051.
Language: English
Subfield: Immunology
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7225139842
Cites:
Cited by:
Related to: 10